Adenoid Cystic Carcinoma

Small-molecule tyrosine kinase inhibitors such as lenvatinib and axitinib may provide disease stabilization in adenoid cystic carcinoma, although tumor shrinkage is uncommon and toxicity limits their long-term use. For most patients without a targetable alteration, platinum-based combinations remain the pragmatic choice, though expectations for benefit should be tempered. Future strategies will likely hinge on optimizing biomarker-driven therapies, expanding access to antibody-drug conjugates, and pursuing collaborative trial designs to overcome the rarity and heterogeneity of these tumors.

Our data support the clinical implementation of a tailored, histology-driven MP algorithm, potentially optimizing the genomic testing resources in SGCs.

They also wish to apologize to the readership of the Journal for any inconvenience caused. [Molecular Medicine Reports 12: 3432‑3438, 2015; DOI: 10.3892/mmr.2015.3815].

Breast ACC is a rare type of TNBC that reportedly has indolent biologic behavior. Definitive preoperative diagnosis remains challenging using imaging modalities alone, as conclusive identification relies heavily on histopathological and immunohistochemical examinations.

This case highlights ACC's propensity for "benign-mimicking" sonographic features (well-defined margins, posterior enhancement, hypovascularity), contributing to misdiagnosis. It underscores that integrating elastography (for assessing stiffness), contrast-enhanced ultrasound (for evaluating washout patterns), CT/MRI (for detecting suspicious perineural spread), and molecular biomarkers (e.g., low Ki-67) is crucial to improving diagnostic accuracy and optimizing follow-up management for ACC.

P2, N=100, Not yet recruiting, Eye & ENT Hospital of Fudan University

We report here an exceedingly rare case of a benign neoplasm diagnosed as benign tubular SG adenoma that was unexpectedly found to harbor a MYBL1::NFIB fusion gene. This case expands the spectrum of SG tumors driven by fusions of MYBL1, and challenges the specificity of MYBL1 fusions for cutaneous AdCC.

P1, N=30, Recruiting, Brigham and Women's Hospital | Not yet recruiting --> Recruiting | N=20 --> 30 | Trial completion date: Jan 2025 --> Nov 2031 | Trial primary completion date: Oct 2024 --> Mar 2031

In addition, we discuss how nociceptor signaling and adenosinergic signaling intersect with Schwann-cell programs to regulate the balance between perineural immunosuppression and anti-tumor immunity. The purpose of this article is to define PNI as a neuro-immune niche in head and neck cancer and delineate biomarker-guided therapeutic strategies for clinical testing.

A balanced translocation in MYB-NFIB fusion gene appears to be fundamental in the pathogenesis. Surgery forms the mainstay treatment option followed by adjuvant radiation in high risk cases, as extrapolated from studies in salivary gland tumour.

By applying multiplex immunofluorescence for selected markers, we validated the presence of the separate cell entities. Our findings provide deeper insights into the biology of PTBTs, which may be beneficial for advancing the diagnosis and therapy of PTBTs.